A.Macquarrie is running all around town telling the instos that acrux is not gaining any traction.There are a couple of matters that will be causing them concern.they are not getting alot of stock to cover their positions.2.on the 1st of january cvs caremark (22 million members) are cutting androgel and testim from their reimbursements and putting axiron as their preferred supplier.3.Eli lilly is gearing up their advertising and their supplies of axiron.4.Market share is currently 13.5% and again growing.5.insurance rebates are significantly better that Macquarrie are modelling.6.Potential conflict /shorter /private clients advisor .7 Any patent extension will add $1 dollar to the price 8.From what i am hearing from my broking sources the smart money is nibbling away waiting for the tide to turn in the new year.
ACR Price at posting:
$2.76 Sentiment: ST Buy Disclosure: Held
